Nutra Pharma Corp (NPHC)

[AChE MD]

Please turn your immediate attention to Nutra Pharma Corp. (NPHC).


Great Article that just appeared in my inbox today.. from BullishCharts.


Are you looking for a high-flying stock that still has some fuel in the tank? If so, you'll be happy to hear about what we have in store for you!


The red-hot biotech Company is working on treatments that could be worth billions, and successes with them could push its stock price through the roof.

NPHC specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain.

The Company just released a corporate update that is sure to grab the attention of the Street.

NPHC announced its plans to increase brand awareness, online visibility and product messaging. This included the engagement of professional marketing teams as well as internet influencers to support product outreach. Nutra Pharma also announced improvements in their laboratory and manufacturing space, launching private label brands, hiring additional quality personnel, engaging new intellectual property attorneys, filing new patents and trademarks as well as engaging government consultants to aid in garnering potential grants, earning government contracts and increasing retail awareness.

In addition to this NPHC's chart appears to be pointing towards a potential breakout.

As of this email, Barchart was reporting this profile to have at least 9 triggered technical buyside indicators across the short, medium, and long terms.

Here's a complete list:

Short Term Indicators

20 Day Moving Average
20 - 50 Day MACD Oscillator
20 - 200 Day MACD Oscillator
Medium Term Indicators

50 Day Moving Average
50 - 200 Day MACD Oscillator
Long Term Indicators

100 Day Moving Average
150 Day Moving Average
200 Day Moving Average
100 - 200 Day MACD Oscillator
On top of that, NPHC was also trading above its 5-Day Exponential Moving Average (EMA) and its 13-Day Exponential Moving Average.

Furthermore, its 5-Day EMA was trading above its 13-Day EMA which signals a profile that is trending in a bullish manner recently.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®, Luxury Feet™, Equine Pain-Away™ and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com
http://www.equinepainaway.com
http://www.luxuryfeet.com

The Biden Administration Could Serve As A Major Catalyst For A NPHC Bull Rally

Among all of the overwhelming and depressing statistics associated with the coronavirus pandemic, here's one number that has sometimes been overlooked: 81,003 people in the U.S. died from drug overdoses in the 12-month period that ended in June 2020. That was a 20% year-over-year increase to a record high, due largely to a sharp surge in overdose deaths after COVID-19 struck. The combination of the added stressors of the pandemic and addicts' inability to access support and treatment proved devastating to many.

That's just one reason President Biden's recent budget proposal calls for $10.7 billion to fight the country's opioid addiction crisis. His proposal focuses on at-risk communities, and increases funding for everything from prevention to recovery programs. If the president gets his way, companies that are built to fight this growing epidemic could see a major lift!

The Perfect Stock To Battle The Opioid Epidemic

Chronic Pain is the leading cause for seeking medical aid in the U.S. A study undertaken by the Centres for disease control and prevention (CDC) in conjunction with NIH and other entities titled “Morbidity and Mortality Weekly Report (MMWR)”in the year 2016, estimates that 20.4% percent of the adults population in the U.S suffered from chronic pain, while 8 percent had high-impact chronic pain limiting at least one important activity in their daily life. Untreated or undertreated chronic pain contributes to$560 billion each year in direct medical costs, lost productivity, and disability programs in the U.S alone.

The global analgesic market is poised to amass $ 26.4 billion by 2022 , growing at a CAGR of 7.1% during 2015 – 2022 , according to a report titled “Analgesics Market by Type (Non-opioids, Opioids) and Route of Administration (Oral, Intravenous, Rectal, Transdermal, Topical) – Global Opportunity Analysis and Industry Forecast, 2015 – 2022” published by alliedmarketresearch.

The Analgesic market is broadly divided into Opioid and Non-Opioid therapeutics. Opioid based medicine has given rise to an addiction endemic with prescription drug overdose becoming one of the leading causes of preventable deaths in the U.S in turn prompting the government to declare a public health emergency in 2017.

This has resulted in growth in the non-opioid based drugs segment, with increasing emphasis being laid on research and development in finding non-opioid alternatives to managing chronic pain. According to a study published by BBC research named “Non-opioid Pain Treatment: Global Markets to 2022” the global market for non-opioid pain treatment which was $ 9.9 billion in 2017, is estimated to grow at a CAGR of 18% and reach $ 22.6 billion by 2022.

An increase in the geriatric population along with a rise in life-style related ailments and chronic diseases will drive the growth in the non-opioid market, along with a favourable government and regulatory environment, increased spending on research and development and fast track approvals for breakthroughs.

How Does NPHC Aim To Battle Chronic Pain?

Currently, Nutra Pharma Corporation offers several proprietary drug products for sale for the treatment of pain: Nyloxin® - the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, Nyloxin® Extra Strength - the only non-prescription pain reliever for severe (Stage 3) pain and Pet Pain-Away™ - the first OTC product to treat pain in companion animals without side effects.

Nyloxin provides all-natural anti-inflammatory analgesic pain relief that is non-toxic, non-narcotic, non-addictive, non-steroidal and contains no aspirin or acetaminophen.

NPHC's Nyloxin Is 100% Safe To Treat Chronic Arthritis And Joint Pain

Nyloxin is believed to work by targeting some of the same receptors on nerve cells that are also recognized by nicotine. These receptors are found in nerves outside the central nervous system (brain and spinal cord) and they are also found on cells of the immune system. Specialized proteins in Nyloxin block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off. In some clinical studies, Nyloxin pain relieving products could provide prolonged chronic muscle and joint relief.

NPHC Is Also Working On Treatments For Viral And Neurological Diseases In Humans

Nutra Pharma is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of Nutra Pharma's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from cobras.

Leading Drug Candidates

RPI-MN

RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and AIDS. It is being developed first for the treatment of HIV. and Herpes.

RPI-78M

RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological and autoimmune disorders that may be served by RPI-78M include myasthenia gravis (MG), rheumatoid arthritis (RA) and amyotrophic lateral sclerosis (ALS).

*RPI-78M has received Orphan Drug Designation from the FDA for the treatment of Pediatric Multiple Sclerosis

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification and possess several desirable properties as drugs, including:

They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.
They display no serious adverse side effects following years of investigations in humans and animals.
They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.
They are easy to administer.
RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.
Conditions

Nutra Pharma is taking on some of the world's most difficult diseases including:

RPI-MN: Modified Cobra Venom for Viral Diseases

Herpes

Herpes is a group of related diseases marked by the development of blisterlike sores on the skin or mucous membranes of the body.

Human Immunodeficiency Virus (HIV / AIDS)

The Human Immunodeficiency Virus (HIV) is the virus that causes AIDS, a debilitating and deadly disease of the human immune system. The World Health Organization (WHO) estimates that 35 million people have died from AIDS since 1981. It is estimated that at the end of 2016, there were more than 36 million people worldwide living with HIV.

RPI-78M: Modified Alpha Cobratoxin for Autoimmune Diseases

Adrenomyeloneuropathy (AMN)

Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 20,000 people globally. Its symptoms are very similar to those of progressive Multiple Sclerosis (MS).

Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system causing muscular weakness, loss of coordination, and speech and visual disturbances. There are approximately 2,000,000 people living with MS worldwide.



NPHC Achieves Several Milestones This Summer

The past few months have been packed with potential bullish catalysts for NPHC.

Below are some of the Company's most recent achievements:

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Nutra Pharma has filed an updated provisional patent for the protection of their intellectual property surrounding the use of RPI-78M and analogs of the drug as potential counter-measures against organophosphate nerve agents

NPHC has filed a new provisional patent to protect their intellectual property surrounding their development of nerve agent counter measures.

"We originally announced this project in early 2018,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “In much the same way that our therapies protect the nerves of patients with disease, our findings indicate that we may protect against – or at least mitigate the damage caused by - nerve agents that are utilized as chemical weapons; such as sarin gas and VX,” he continued. “As we have pursued this project and gathered additional data, we are now filing new and updated intellectual property surrounding these findings and will be working with experts in the field to have our products in testing shortly. To that end, we will be working with governmental agencies, Universities and private collaborators as we seek to further this research and potentially license the technology,” he concluded.

Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may disrupt the transfer of messages to organs through the nerves. This disruption is caused by the over-stimulation of certain receptors on the surface of the neurons. These same receptors are the target of Nutra Pharma’s drugs, which may block the action of the nerve agents or minimize the damage that they may cause.

RPI-78M was originally derived from an extract of cobra venom and is an antagonist of the nicotinic acetylcholine receptor. The drug has a remarkably low toxicity with a very large therapeutic window. Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death. Furthermore, it is expected that RPI-78M may be beneficial in neuromuscular disorders where the activity of nicotinic acetylcholine receptor has been compromised. The proprietary technology is covered by patents describing the application and use of RPI-78M in the treatment of autoimmune diseases, including Multiple Sclerosis (MS).

“The company has very encouraging in vivo and in vitro preclinical data, a demonstrated molecular mechanism of action and a robust scientific rationale for the continued commercial development of its nerve agent counter measure,” reported Dale VanderPutten, PhD, Chief Scientific Officer of Nutra Pharma. “The use of organophosphate nerve weapons (Soman, VX, Novichok, etc) is unfortunately increasing,” he continued. “The successful use of these weapons by states and terrorist groups regretfully emboldens others to use them as well. These weapons are also becoming increasingly sophisticated without any advancements in new protective agents. We believe that our nAChR-directed countermeasure may provide an important tool for military and civilian defenses against these horrifying weapons,” Dr. VanderPutten concluded.

In November, Nutra Pharma announced that Dr. VanderPutten was invited by the Defense Threat Reduction Agency (DTRA) to present their nerve agent countermeasure technology in a Tech Watch talk to an audience of military and civilian experts in chem/bio defense. Earlier this year, the Company announced that they had engaged new IP attorneys at Christopher & Weisberg P.A. to work on patents and trademarks for Nutra Pharma’s products and technologies. Additionally, the Company announced recently that they had engaged the Washington DC-based government affairs consulting firm, Vitello Consulting to work with elected officials as well as governmental agencies to increase the awareness of Nutra Pharma’s products and technologies with the goal of improving sales, garnering grants and potentially speeding drug applications.

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs

NPHC announced their plans for increasing sales of their over-the-counter pain relievers through private label agreements that will rebrand Nyloxin. The first private label distributor contract has been executed with sales expected to start within the next 4-6 weeks. Their marketing plan includes direct sales, targeted landing pages and aggressive marketing through social media.

"We have been working diligently to brand our amazing products over the last few years and we have seen some consistent growth in online sales as well as into physician offices and small-chain pharmacies," commented Nina Goldstein, Marketing Manager of Nutra Pharma. "We will continue these efforts, but will be adding another sales layer by allowing expanded branding of our product technology through private labels with professional marketers and distributors," she continued. "This will allow increased sales to Nutra Pharma by expanding our customer base into markets not currently available to us. We have had small distribution through private labels in the past, but these new efforts will utilize developed sales channels that should see rapid growth and increase the overall awareness of our core technology; the use of cobra venom in the treatment of chronic pain and inflammation," she concluded.

Nyloxin® is a safe, non-narcotic, and non-addictive Homeopathic pain reliever for the relief of pain without impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies. Nyloxin is available as an oral spray for systemic pain and as a topical gel for targeted pain management.

NPHC Announces Exciting News Out Of D.C.

Nutra Pharma is working with Washington DC-based government affairs consultants and lobbyists to support their Nyloxin® line of pain relief products as well as act as liaisons to governmental agencies

NPHC has engaged the Washington DC-based government affairs consulting firm, Vitello Consulting. The firm will work with elected officials as well as governmental agencies to increase the awareness of Nutra Pharma’s products and technologies with the goal of improving sales, garnering grants and potentially speeding drug applications.

“We are excited to work with Vitello Consulting as our liaisons with governmental agencies and elected officials,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We have high hopes that this relationship will allow us to get our products into the hands of the people that need them most. This includes our Veterans in chronic pain,” he continued. “One of the first projects for this new relationship will be working with the Veterans Administration to pave the way into VA hospitals and clinics. They will also help us navigate government bureaucracies that include the FDA, the SEC and buyers on the Federal Supply Schedule,” he concluded.

Nutra Pharma has several projects in front of governmental agencies at this time. The Company has previously announced their work with the Defense Threat Reduction Agency (DTRA) on their potential nerve agent counter-measures. Nutra Pharma had also been granted Orphan Designation by the FDA for their Multiple Sclerosis drug, RPI-78M and has stated plans to move the drug into clinical trials.

“We’re thrilled to be working with Nutra Pharma”, commented Frank Vitello, president of Vitello Consulting. “The pipeline Rik and his team have developed has them positioned for immediate success, and I’m confident that together we’ll cross the goal line on a number of these projects in the coming months,” he concluded.

NPHC's Nyloxin® Expands Its Sales Presence

Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin(R) line of pain relief products to their marketplace

NPHC announced that Diverse Health Services of Metro-Detroit has added the Nyloxin line of products to their offerings. Nyloxin is already being sold in-house at their facilities and will be added shortly to their online marketplace. Their marketing plan includes direct sales to patients and other medical facilities, sales through their websites and social media utilizing their online platforms as well as videos featuring Dr. R.E. Tent.

"We are pleased to be working with Diverse Health Services and Dr. Tent to expand the marketing of Nyloxin," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Nyloxin is already being sold in physician offices, clinics and small-chain pharmacies: and we've been working diligently to introduce Nyloxin into the Chiropractic and Complementary medicine marketplace," he continued. "As a recognized voice in that community, Dr. Tent is the perfect distribution partner to open those doors and greatly expand the awareness of our products," he concluded.

Dr. R.E. Tent is a graduate of Palmer College of Chiropractic. He has "Diplomat" status in the National Board of Chiropractic Examiners and is a member of the International Pain Control Institute. Dr. Tent also has a PhD in Clinical Nutrition. He has a highly successful local private practice in Novi, Michigan and is renowned all over the country for his results in chiropractic and alternative treatment. Dr. Tent regularly lectures and creates video content for his websites. His first audiotape, "Kill the Cravings" has been distributed globally. His lectures continue twice a year and his past lectures are available on YouTube and DVD.

"We're always looking for natural alternatives to the potentially dangerous pain relievers on the market today," stated Dr. Randall Tent, DC ND PhD. "We're excited to be working with Nutra Pharma and we believe that these products will be huge for the Alternative Medicine and Chiropractic communities," he continued. "I've personally used the products after playing hockey and I've seen the incredible results for myself. I believe that this could become the solution for people with uncontrollable pain," he concluded.

Technical Analysis

NPHC's Chart Appears To Be Trending Bullish

As we mentioned above, NPHC's chart appears to be pointing towards a potential breakout.

As of this email, Barchart was reporting this profile to have at least 9 triggered technical buyside indicators across the short, medium, and long terms.

Here's a complete list:

Short Term Indicators

20 Day Moving Average
20 - 50 Day MACD Oscillator
20 - 200 Day MACD Oscillator
Medium Term Indicators

50 Day Moving Average
50 - 200 Day MACD Oscillator
Long Term Indicators

100 Day Moving Average
150 Day Moving Average
200 Day Moving Average
100 - 200 Day MACD Oscillator
On top of that, NPHC was also trading above its 5-Day Exponential Moving Average (EMA) and its 13-Day Exponential Moving Average.

Furthermore, its 5-Day EMA was trading above its 13-Day EMA which signals a profile that is trending in a bullish manner recently.

NPHC closed last session near its high-of-day price, while trading on higher than average volume.

A strong close like that tends to be a strong indicator of momentum turning bullish.

If NPHC continues trading how it’s been, we could see a potential move past $0.01!

The Bottom Line

Are you looking for a high-flying stock that still has some fuel in the tank? If so, you should start your research on NPHC, and add it to the top of your watchlist immediately!

This could be the last time you see it at these levels!

(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)

Best regards,



The BullishCharts Team